COVID-19 Vaccine (inactivated, adjuvanted) Valneva (COVID-19 vaccine (inactivated, adjuvanted, adsorbed))
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- COVID-19 vaccine (inactivated, adjuvanted, adsorbed)
- Company
- Valneva Austria GmbH
- Status
- Withdrawn
- Therapeutic area
- COVID-19 virus infection
- CHMP opinion
- Thu 23 Jun 2022
- EU approval
- Fri 24 Jun 2022
- Designations
- Additional monitoring
- Application
- EMEA/H/C/006019
- ATC
- J07BX03
- Official record
- www.ema.europa.eu
Indication
COVID-19 Vaccine (inactivated, adjuvanted) Valneva is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 to 50 years of age. The use of this vaccine should be in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Follow COVID-19 Vaccine (inactivated, adjuvanted) Valneva
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.